Teva and Celltrion Announce the Availability of TRUXIMA (rituximab-abbs) Injection, the First Biosimilar to Rituxan (rituximab) in the United States -…
By daniellenierenberg
JERUSALEM & PARSIPPANY, N.J. & INCHEON, South Korea--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Celltrion, Inc., (KRX KRX:068270) and Celltrion Healthcare, Co., Ltd. (KRX KOSDAQ:091990), today announced that TRUXIMA (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan1 (rituximab) now available in the United States with a full oncology label. TRUXIMA is currently indicated for the treatment of adult patients with non-Hodgkins Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL):
We are excited about the first FDA-approved biosimilar to rituximab in the U.S., stated Brendan OGrady, Executive Vice President and Head of North America Commercial at Teva. Tevas commitment to biosimilars is focused on the potential to create lower healthcare costs and increased price competition. This focus is consistent with Tevas mission of making accessible medications to help improve the lives of patients.
TRUXIMA was approved by the U.S. Food and Drug Administration (FDA) as the first rituximab biosimilar. The approval was based on a review of a comprehensive data package inclusive of foundational and extensive analytical characterization, nonclinical data, clinical pharmacology, immunogenicity, clinical efficacy, and safety data. In May 2019, the FDA approved TRUXIMA to match all of the reference products oncology indications for NHL and CLL. In light of a patent settlement with Genentech, Celltrion and Teva have a pending FDA submission for rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA), and a license from Genentech to expand the TRUXIMA label to include these indications in Q2 2020.
We are pleased to announce the launch of the first rituximab biosimilar, TRUXIMA, with our marketing partner Teva in the U.S. said Mr. Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We believe that the introduction of TRUXIMA into the U.S. market will contribute to addressing unmet needs of U.S. patients as well.
The Wholesale Acquisition Cost (WAC or list price) for TRUXIMA will be 10 percent lower than the reference product. TRUXIMA is being made available through primary wholesalers at a WAC of $845.55 for 100mg vial and $4227.75 for 500mg vial. Actual costs to individual patients and providers for TRUXIMA are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patients insurance payer and eligibility for participation in the assistance program.
Dedicated patient support services are also available from Teva through the Comprehensive Oncology Reimbursement Expertise (CORE) program. CORE is available to help eligible patients, caregivers and healthcare professionals navigate the reimbursement process. CORE offers a range of services, including benefits verification and coverage determination, support for precertification and prior authorization, assistance with coverage guidelines and claims investigation, and support through the claims and appeals process. A savings program is also available for eligible commercially insured patients. To learn more, please visit TevaCORE.com. For healthcare professionals seeking additional information, there is also a dedicated site at TRUXIMAhcp.com.
Celltrion and Teva Pharmaceutical Industries Ltd. entered into an exclusive partnership in October 2016 to commercialize TRUXIMA in the U.S. and Canada.
Please see the Important Safety Information below including the Boxed Warning regarding fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. For more information, please visit the full prescribing information.
Important Safety Information
WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
Infusion-Related Reactions - Administration of rituximab products, including TRUXIMA, can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue TRUXIMA infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions
Severe Mucocutaneous Reactions - Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab products
Hepatitis B Virus (HBV) Reactivation - HBV reactivation can occur in patients treated with rituximab products, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with TRUXIMA. Discontinue TRUXIMA and concomitant medications in the event of HBV reactivation
Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab products
Warnings and Precautions
Infusion-Related Reactions - Rituximab products can cause severe, including fatal, infusion-related reactions. Severe reactions typically occurred during the first infusion with time to onset of 30-120 minutes. Rituximab product-induced infusion-related reactions and sequelae include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, anaphylactoid events, or death.
Premedicate patients with an antihistamine and acetaminophen prior to dosing. Institute medical management (e.g. glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. Depending on the severity of the infusion-related reaction and the required interventions, temporarily or permanently discontinue TRUXIMA. Resume infusion at a minimum 50% reduction in rate after symptoms have resolved. Closely monitor the following patients: those with pre-existing cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (>25,000/mm3)
Severe Mucocutaneous Reactions - Mucocutaneous reactions, some with fatal outcome, can occur in patients treated with rituximab products. These reactions include paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of these reactions has been variable and includes reports with onset on the first day of rituximab exposure. Discontinue TRUXIMA in patients who experience a severe mucocutaneous reaction. The safety of re-administration of rituximab products to patients with severe mucocutaneous reactions has not been determined.
Hepatitis B Virus Reactivation - Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs classified as CD20-directed cytolytic antibodies, including rituximab products. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive. Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive).
HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA levels or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, i.e., increase in transaminase levels. In severe cases increase in bilirubin levels, liver failure, and death can occur.
Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with TRUXIMA. For patients who show evidence of prior hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before and/or during TRUXIMA treatment.
Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following TRUXIMA therapy. HBV reactivation has been reported up to 24 months following completion of rituximab therapy.
In patients who develop reactivation of HBV while on TRUXIMA, immediately discontinue TRUXIMA and any concomitant chemotherapy, and institute appropriate treatment. Insufficient data exist regarding the safety of resuming TRUXIMA treatment in patients who develop HBV reactivation. Resumption of TRUXIMA treatment in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing HBV.
Progressive Multifocal Leukoencephalopathy (PML) - JC virus infection resulting in PML and death can occur in rituximab product-treated patients with hematologic malignancies. The majority of patients with hematologic malignancies diagnosed with PML received rituximab in combination with chemotherapy or as part of a hematopoietic stem cell transplant. Most cases of PML were diagnosed within 12 months of their last infusion of rituximab.
Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture.
Discontinue TRUXIMA and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.
Tumor Lysis Syndrome (TLS) - Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, sometimes fatal, can occur within 12-24 hours after the first infusion of rituximab products in patients with NHL. A high number of circulating malignant cells (>25,000/mm3) or high tumor burden, confers a greater risk of TLS.
Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for TLS. Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.
Infections - Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of rituximab product-based therapy. Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure). New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. Discontinue TRUXIMA for serious infections and institute appropriate anti-infective therapy. TRUXIMA is not recommended for use in patients with severe, active infections.
Cardiovascular Adverse Reactions - Cardiac adverse reactions, including ventricular fibrillation, myocardial infarction, and cardiogenic shock may occur in patients receiving rituximab products. Discontinue infusions for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of TRUXIMA for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina.
Renal Toxicity - Severe, including fatal, renal toxicity can occur after rituximab product administration in patients with NHL. Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. The combination of cisplatin and TRUXIMA is not an approved treatment regimen. Monitor closely for signs of renal failure and discontinue TRUXIMA in patients with a rising serum creatinine or oliguria.
Bowel Obstruction and Perforation - Abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving rituximab in combination with chemotherapy. In postmarketing reports, the mean time to documented gastrointestinal perforation was 6 (range 1-77) days in patients with NHL. Evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur.
Immunization - The safety of immunization with live viral vaccines following rituximab product therapy has not been studied and vaccination with live virus vaccines is not recommended before or during treatment.
Embryo-Fetal Toxicity - Based on human data, rituximab products can cause fetal harm due to B-cell lymphocytopenia in infants exposed to rituximab in-utero. Advise pregnant women of the risk to a fetus. Females of childbearing potential should use effective contraception while receiving TRUXIMA and for 12 months following the last dose of TRUXIMA.
Most common adverse reactions in clinical trials of NHL (>25%) were: infusion-related reactions, fever, lymphopenia, chills, infection, and asthenia
Most common adverse reactions in clinical trials of CLL (>25%) were: infusion-related reactions and neutropenia
Nursing Mothers - There are no data on the presence of rituximab in human milk, the effect on the breastfed child, or the effect on milk production. Since many drugs including antibodies are present in human milk, advise a lactating woman not to breastfeed during treatment and for at least 6 months after the last dose of TRUXIMA due to the potential for serious adverse reactions in breastfed infants.
About TRUXIMA
TRUXIMA (rituximab-abbs) is a U.S. Food and Drug Administration (FDA)-approved biosimilar to RITUXAN (rituximab) for the treatment of adult patients with CD20-positive, B-cell NHL to be used as a single agent or in combination with chemotherapy or CLL in combination with fludarabine and cyclophosphamide (FC).
TRUXIMA has the same mechanism of action as Rituxan and has demonstrated biosimilarity to Rituxan through a totality of evidence.
About Celltrion Healthcare, Co. Ltd.
Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcares products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.
About Celltrion, Inc.
Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA approval for TRUXIMA (rituximab-abbs) and HERZUMA (trastuzumab-pkrb) in 2018.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.
Teva's Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding TRUXIMA, which are based on managements current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Quarterly Reports on Form 10-Q for the first and second quarter of 2019 and in our Annual Report on Form 10-K for the year ended December 31, 2018, including in the sections captioned "Risk Factors and Forward Looking Statements. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
1 RITUXAN is a registered trademark of Genentech and Biogen.
Read this article:
Teva and Celltrion Announce the Availability of TRUXIMA (rituximab-abbs) Injection, the First Biosimilar to Rituxan (rituximab) in the United States -...
- 001 Cardiac Stem Cell Therapy [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- 002 Wow! UW Research labs [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- 003 cellalign [Last Updated On: June 28th, 2011] [Originally Added On: June 28th, 2011]
- 004 Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional? [Last Updated On: August 25th, 2011] [Originally Added On: August 25th, 2011]
- 005 Designer Life: repair brain, heart with stem cells - Future Health keynote speaker [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 006 Cardiac Stem Cell Therapy at Rostock University [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 007 Stem Cells: Mending a broken heart? [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 008 Cardiovascular Derivatives of Embryonic Stem Cells in Cardiac Repair and Drug Discovery [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 009 Stem Cell Therapy in Cardiac Disease [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 010 Cardiac Recovery Points to Adult Stem Cells [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 011 Oral Surgeon utilizes StemSave to preserve stem cells in wisdom teeth to combat cardiac disease [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 012 Stem Cells and Cardiac Regeneration [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 013 Dr Victor Dzau on Stem Cells for Cardiac Repair. [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 014 Cardiomyogenic differentiation of Mesenchymal Stem cells (KUM2/9-15c) [Last Updated On: September 4th, 2011] [Originally Added On: September 4th, 2011]
- 015 Heart Failure Patient After Adult Stem Cell Therapy [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 016 Stem Cell operation in Cardiac Surgery-Al-Jazeerah [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 017 Heart Disease Patient Describes His Stem Cell Treatment [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- 018 Cardiovascular Therapies: Spotlight on Stem Cell Research - Douglas Boyd [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 019 Adult Stem Cell [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 020 Heart repair using own stem cells after heart attack: Future Health keynote speaker [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 021 Stem Cell #8 Vas Cath Removal 04/28/11 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 022 Adult Stem Cells Used To Rebuild Heart Tissue Video. More at http://www.stemcellfusion.com [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 023 Davos Question: Stem Cell Answer [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- 024 Did you have a Heart Attack and Need to Recover your Cardiac Muscle? [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- 025 Cardiac Tissue Can Regenerate [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- 026 William F. Testimonial of Treatment Stem Cell [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- 027 Stem Cell Heart Surgery must see [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 028 Valentine's Day Stem Cell Wish: Mending Broken Hearts [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 029 Advanced Cell Technology OneMedForum 2011 [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 030 Human 2.0: The Helix of Our Future [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 031 heart cell generation from human ES and iPS cells (embryonic and induced pluripotent stem cells).flv [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 032 Stem Cell Therapy and Stem Cell Treatment with Dell [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 033 UCD Med Student Receives Fulbright Award [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 034 Cardiomyocytes derived from mouse Embryonic stem cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 035 Immune Control of Stem Cell Mobilization [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 036 Better Drugs Through Stem Cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 037 stem cell derived cardiomyocytes [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 038 Stem Cells: Heart cells grown from mouse stem cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 039 Patel Stem Cell Heart Failure [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 040 Turning Adult Stem Cells into Medicine - Zannos Grekos, MD [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 041 Kevin's 2 Heart Transplants and Stem Cell Transplant [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 042 Breakthrough in Stem cell technology [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 043 Affordable Stem Cell Therapy in Guatemala (2hrs from Miami) [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 044 Cadiomyogenesis of human mesenchymal stem cells [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 045 Mark Mercola: Differentiating embryonic stem cells into adult tissues [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 046 Cardiomyocytic differentiation of endometrial stem cells. [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 047 Adult Stem Cell vs Embryonic Stem Cell Research Ethics Video [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- 048 Pt. 1--Dr. Ali Denktas--Stem Cells as Markers after Myocardial Infarctions [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- 049 Repairing Damaged Hearts with Stem Cells [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- 050 Mouse GEN cells overexpressing Csx/Nkx2.5 and GATA4 behave like transient amplifying cells [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- 051 20100804_axiogenesis.wmv [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- 052 Beating Cardiomyocytes from E14 Cells [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- 053 Heart cells grown from human embryonic stem cells [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- 054 First US Patient In Stem Cell Transplant [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- 055 Be still my beating stem cell heart [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- 056 Beating Human Heart Cells from Embryonic Stem Cells [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- 057 Spontaneously and rhythmically beating engineered human heart tissue from pluripotent stem cells [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- 058 Cardiac Stem Cell Therapy - How it works [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- 059 Doctors To Use 'Trained' Stem Cells To Heal Heart [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 060 Beating Heart Stem Cells [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 061 AM RADIO, DR. AMIT PATEL AND STEM CELLS SAVED MY LIFE - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 062 New heart built with stem cells - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- 063 Adult Stem Cells For Heart Disease: Today's Reality - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- 064 H9 beating stem cells - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- 065 Double Blind Trial of Stem Cells for Heart Failure - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- 066 Repairing Damaged Hearts with Stem Cells - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- 067 Cardiac differentiation of hES cells at 20x - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- 068 SPRAY-ON STEM CELLS - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- 069 Stem Cells: A smart use for wisdom teeth - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- 070 VistaGen's Stem Cell Derived Cardiomyocytes - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- 071 Stem Cell Research [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- 072 The Power of Stem Cells - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- 073 Beating iCell® Cardiomyocytes - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 074 SCIPIO: Cardiac stem cells and postinfarction heart failure - Video [Last Updated On: November 15th, 2011] [Originally Added On: November 15th, 2011]
- 075 Beating Cardiomyocytes in Cell Culture - Video [Last Updated On: November 15th, 2011] [Originally Added On: November 15th, 2011]
- 076 Stem Cells Heal Heart Attack Damage. - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 077 C2CAM - 2011.11.15 - Dulce Base - Regenerative Medicine - Info - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 078 Latest Update on Stem Cell Research at UW - Dr. Timothy Kamp - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 079 Coast To Coast AM: Regenerative Medicine / Dulce Base 11-15-2011 Download Link - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 080 C2CAM - 2011.11.15 - Dulce Base - Regenerative Medicine - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
